In company news, Dyax Corp. (NASDAQ:DYAX) shares fell Friday after the biotech company priced a public offering of 8 million shares of its common stock at $9.25 each, a 9% discount to Thursday’s closing price and generating around $74 million in gross proceeds. Dyax Corp. (NASDAQ:DYAX) shares fell -9.11% in last trading session and ended the day on $9.23. DYAX return on equity ratio is recorded as 101.70% and its return on assets is -34.40%. Dyax Corp. (NASDAQ:DYAX) yearly performance is 126.23%.
The Piedmont Club will hold its monthly Conversations in Leadership from 11:30 a.m. to 1 p.m. Friday at the club, 200 W. Second St. The program will be on “Leading Change.” The panelists will be Karal Yena, a consultant; Sarah Williamson, the executive director of the Forsyth Humane Society; Gayle Tuch, an attorney and former president of Yadkin Riverkeeper; and Tim Betram of Tengion, Inc. (OTCMKTS:TNGN). Ana Tampanna, a leadership development coach will be the moderator. Tengion, Inc. (OTCMKTS:TNGN) shares advanced 16.38% in last trading session and ended the day on $0.270. TNGN return on equity ratio is recorded as -71.90% and its return on assets is -56.60%. Tengion, Inc. (OTCMKTS:TNGN)yearly performance is 94.74%.
Omeros Corporation (NASDAQ:OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, announced recent highlights and financial results for the fourth quarter and year ended December 31, 2013, which include: 4Q 2013 net loss of $1.8 million, or $0.05 per share, and for the full year of 2013 a net loss of $39.8 million, or $1.39 per share Operating expenses in 4Q 2013 were $14.1 million including $2.4 million of non-cash expenses, and for the full year of 2013 were $52.1 million including non-cash expenses of $9.7 million. U.S. and European regulators accepted Omidria™ (OMS302) marketing applications for review. Omeros’ OMS721 received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for complement-mediated thrombotic microangiopathies (TMAs). Omeros Corporation (NASDAQ:OMER) shares moved down -7.72%in last trading session and was closed at $11.35, while trading in range of $11.00 – $11.59. Omeros Corporation (NASDAQ:OMER) year to date (YTD) performance is 0.53%.
Wells Fargo increased its price target on Five Prime Therapeutics Inc (NASDAQ:FPRX) as the firm thinks the company’s novel immunotherapy treatment targets have significant potential, and will likely enable the company to sign a partnership in the near-term. The firm continues to believe that the stock does not adequately reflect the company’s long-term potential, and it keeps an Outperform rating on the shares. Five Prime Therapeutics Inc (NASDAQ:FPRX) weekly performance is 19.88%. On last trading day company shares ended up $18.75. Five Prime Therapeutics Inc (NASDAQ:FPRX) distance from 50-day simple moving average (SMA50) is 14.85%. Analysts mean target price for the company is $21.33.